NeuroSense Therapeutics plans to enroll 70 patients with fast-progressing amyotrophic lateral sclerosis (ALS) in its planned Phase IIb trial of PrimeC, CEO Alon Ben-Noon says. The trial will randomise patients 2:1 between PrimeC and placebo during a blinded six-month treatment period, followed by a six-month, open-label treatment period, he adds. PrimeC is an extended-release version […]

Alcohol Use Disorder (AUD) affects 6.7% of drinking adults. Some of the symptoms of AUD, as listed by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), include being unable to reduce alcohol use despite a desire to do so, a need to drink that has become distracting, continuing to drink despite harm caused and experiencing symptoms of withdrawal […]

Ophthalmology is approaching a Renaissance as novel therapies are being developed to meet a variety of unmet needs that, with current therapies, may progress to blindness. Oculis S.A. entered this space a few years ago, determined to identify those gaps. Rather than begin with a solution in search of a problem, it started with a thorough […]